Every 10-Q that Marker Therapeutics, Inc. (MRKR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRKR filings page.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing MAR-T cell therapies for hematologic malignancies and solid tumors. For the six months ended June 30, 2026, it reported a net loss of $5,005,507, compared with $8,461,748 a year earlier, driven mainly by lower research and development spending.
Research and development expenses fell to $4,318,888 from $7,312,481, while general and administrative expenses were relatively stable at $2,374,012. Grant income was a meaningful funding source, totaling $1,433,270 in the first half of 2026 from multiple CPRIT, FDA and NIH SBIR awards. The company also disclosed a new $4.2 million U.S. Department of War grant to support MT-601 in relapsed/refractory large B-cell lymphoma.
Cash, cash equivalents, and restricted cash were $11,922,332 as of June 30, 2026, with working capital of $12,165,464. Management expects existing cash to fund operations into the second quarter of 2027, assuming no additional grant inflows, and stated that these conditions raise substantial doubt about its ability to continue as a going concern. Marker plans to seek additional equity financing and grants while advancing its MT-401 and MT-601 programs.
Marker Therapeutics reported Q1 2026 results showing a smaller net loss while remaining pre-revenue. Net loss was $3.2 million compared with $4.4 million a year earlier, helped by lower operating expenses and higher grant income.
The company held $15.6 million in cash, cash equivalents, and restricted cash and working capital of $13.8 million as of March 31, 2026. Management expects existing resources to fund operations into the first quarter of 2027 and discloses substantial doubt about its ability to continue as a going concern without new capital or additional grant funding. The company also increased its authorized common shares from 30 million to 130 million after quarter-end.
Marker Therapeutics (MRKR) filed its Q3 2025 10‑Q, reporting cash, cash equivalents and restricted cash of $18.9M as of September 30, 2025 and total assets of $21.7M. The quarter showed grant income of $1.23M, research and development expense of $2.35M and general and administrative expense of $1.02M, resulting in a Q3 net loss of $2.0M (basic and diluted EPS $0.12 loss).
For the nine months, grant income was $2.44M and operating expenses totaled $13.45M, including a $0.45M loss on early termination of a vendor agreement, leading to a year‑to‑date net loss of $10.46M. The company raised liquidity via ATM sales, issuing 1,624,075 shares for net proceeds of $4.5M between July 17–21, 2025 and 3,734,217 shares for net proceeds of $5.4M on August 26, 2025. Shares outstanding were 16,673,127 as of November 6, 2025.
Management states there is “substantial doubt” about the ability to continue as a going concern, though current resources are expected to fund operations through the third quarter of 2026. The company continues to advance MT‑601 manufacturing via a Cellipont SOW and reports multiple active grants, including CPRIT programs with $1.4M recorded as restricted cash and deferred revenue.
Marker Therapeutics, Inc. reported several financing and grant developments and ongoing clinical spending. The company sold 1,624,075 shares under an ATM between July 17-21, 2025 for net proceeds of $4.5 million at an average $2.87 per share. A private placement closed December 23, 2024 generated approximately $14.9 million of net proceeds. Multiple grants supported R&D: CPRIT AML and pancreatic grants (noted amounts include $11.0 million and $9.5 million grants), an FDA Orphan Products Grant ($2.0 million, $1.1 million received to date), SBIR and NIH awards, and other grants producing recorded grant income and receivables ranging from $0.012 million to $1.3 million. As of June 30, 2025, the company reported $1.9 million in cash (including $1.4 million restricted) and $9.9 million in U.S. government agency securities for aggregate cash, cash equivalents, and restricted cash of $11.8 million, down from $19.2 million as of December 31, 2024. The company granted equity awards (CEO: 50,000 options; non-employee directors: 30,000 options each) at $1.59 strike and disclosed licensing obligations that include royalty payments and up to $64.85 million of potential milestone payments to BCM.